MiniMed Group (NASDAQ: MMED) reported first quarter fiscal year 2027 net sales of $843 million, surpassing analyst consensus estimates of $827.065 million. The Northridge, California-based diabetes technology leader posted organic revenue growth of 15.8% and raised its fiscal year 2027 organic revenue growth guidance to approximately 10.5%.

The company’s adjusted EBITDA for the quarter was $83 million, resulting in a margin of 9.9%. This figure was impacted by a $12 million non-operational foreign exchange remeasurement charge and an acceleration of planned investments totaling approximately $8 million to support key growth initiatives, including the MiniMed Flex launch and the accelerated FDA submission for MiniMed Fit.

Financial Performance

Worldwide net sales grew 16.6% as reported to $843 million, up from $723 million in the same quarter last year. The company benefited from an approximate 4-6% extra week advantage due to its 52-53 week fiscal calendar. Excluding this benefit, MiniMed generated low-double digit organic growth, accelerating from 8.7% in the prior quarter.

U.S. New Pumps Sold grew over 20% year-over-year, driven by the launch of MiniMed Flex and new sensors. Worldwide New Pumps Sold reached approximately 34,000 units, a 7.7% increase. The worldwide Continuous Glucose Monitor (CGM) attachment rate rose to 69%, an increase of approximately 100 basis points quarter-over-quarter.

Analyst Outlook and Ratings

Prior to the release, analysts had expected quarterly earnings of 9 cents per share, a decline from 35 cents per share in the year-ago period. The actual GAAP net income attributable to the company was breakeven ($0), compared to a loss of $19 million in the prior year period.

Several major Wall Street analysts have adjusted their outlooks for MiniMed Group in recent months:

Pipeline and Guidance Updates

MiniMed raised its fiscal year 2027 organic revenue growth guidance to approximately 10.5%, up from prior guidance of approximately 10%. The company reaffirmed its adjusted EBITDA margin guidance of approximately 16% for the full year.

Key pipeline developments include:

• MiniMed Fit patch pump submitted to the U.S. FDA ahead of the fall target, with a full U.S. launch expected in summer 2027.
• MiniMed Flex received CE Mark well ahead of the calendar 2026 year-end target, with commercial launch expected in November.
• Vivera fully-closed loop algorithm U.S. pivotal trial enrollment completed, on track for second half calendar 2027 U.S. launch.
• Next-generation MiniMed extended wear sensor U.S. Investigational Device Exemption approved, with first enrollment in pivotal trial expected this fall.

Corporate Developments

On June 29, MiniMed named Alcon CEO David Endicott and Linnea Burman to its board of directors. Shares of MiniMed Group rose 0.1% to close at $19.51 on Thursday prior to the earnings release.

What the Numbers Show

The divergence between GAAP profitability and adjusted operational metrics highlights the transitional nature of MiniMed’s standalone operations. While GAAP net income was breakeven, adjusted EBITDA margin would have been 12.2% excluding the one-time FX charge and accelerated investments. Furthermore, consumables and CGM together represented 82% of total revenue, underscoring the durability of the company’s recurring revenue stream as it expands its installed base through new pump sales.

MiniMed (NASDAQ: MMED) has begun commercial shipments of the MiniMed Flex system in the United States, now available paired with the Instinct sensor made by Abbott. This launch marks the first time users can combine MiniMed’s smallest and only app-controlled insulin pump with what the company describes as the world’s smallest sensor, which supports up to 15 days of continuous wear.

The MiniMed Flex system is powered by SmartGuard technology, which automatically adjusts insulin delivery around the clock based on real-time glucose levels. It also features Meal Detection technology designed to compensate for occasionally missed boluses or underestimated carbohydrate intake. The device holds up to 300 units of insulin and is compatible with the Extended infusion set, which can be worn for up to seven days.

Clinical Context and Performance

Real-world data from the MiniMed 780G system, which utilizes the same SmartGuard algorithm, indicates that users with recommended settings achieve 80% Time in Range. Overnight Time in Range exceeds 90% according to the cited studies.

Regulatory Status and Eligibility

The MiniMed Flex system is FDA cleared for specific patient demographics in the U.S. market:

• People with type 1 diabetes ages 7 years and older.
• Adults ages 18 years and older with insulin-requiring type 2 diabetes.

Customers can currently order the MiniMed Flex system with either the Instinct sensor or the Simplera Sync sensor.

Strategic Positioning

Que Dallara, chief executive officer at MiniMed, stated that the company aims to deliver technology that reduces the burden of diabetes management. The launch coincides with a new consumer campaign titled "Nothing comes close to freedom you can feel," highlighting the system’s discreet design, app control, and 24/7 automation capabilities.

Monique La Bomme, a user of the MiniMed Flex system with the Instinct sensor, noted that the ability to go longer between sensor changes and use app-based controls allows for less frequent interaction with the device during daily life.